Merck KGaA to Acquire SpringWorks Therapeutics for ~$3.9B
Shots:
- Merck KGaA has entered into a definitive agreement to acquire SpringWorks Therapeutics to strengthen its rare disease portfolio & expand SpringWorks’ reach to markets beyond the US
- As per the agreement, Merck KGaA will acquire SpringWorks for $47/share (~26% premium), with an equity value of ~$3.9B or an enterprise value of ~$3.4B, funded by available cash & new debt, with closing expected in H2’25
- Additionally, SpringWorks' Gomekli (mirdametinib) MAA for NF1-PN pts (≥2yrs.) is under EMA review, with potential approval in 2025, while the MAA for Ogsiveo (nirogacestat) in progressing desmoid tumors is also under EMA review, with a CHMP opinion expected in Q2’25
Ref: Merck KGAA | Image: SpringWorks Therapeutics
Related News:- SpringWorks Therapeutics Receives the US FDA Approval for Ogsiveo (nirogacestat) for the Treatment of Desmoid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
